In late 2024, the US Food and Drug Administration clarified its stance on several key compounds, moving them out of high-risk safety categories
The therapeutic efficacy of Zepbound, Semaglutide, and Wegovy is rooted in their ability to mimic GLP-1 activity
Rybelsus has the same potential side-effects as injectable Semaglutide: nausea, stomach pain, diarrhoea, decreased appetite, constipation, and weight reduction
Sources FDA Import Alert 66-80: Detention Without Physical Examination of Drug Products Containing GLP-1 Receptor Agonists and Certain Peptide Drug Products Federal Food, Drug, and Cosmetic Act Section 801 (Imports) FDA Drug Establishments Current Registration Site (DECRS) FDA: Frequently Asked Questions About Drug Shortages FDA Warning Letters Database PeptideKnow: Supply Chain and Enforcement Are the Real Bottlenecks (Apr 22, 2026) Sources & References FDA PCAC Meeting Announcement (July 23-24, 2026) PBS: FDA to Weigh Easing Limits on Peptides Favored by RFK Jr
They are not provided for general wellness or energy enhancement